Saturday 17 October 2026
Export BIOA’s income statement to Excel — free account
BioAge Labs, Inc.
BIOA Healthcare Drug Manufacturers Specialty & Generic
BioAge Labs, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million. In the quarter to June 2026, revenue grew 1.62%, EPS grew 3.33%, free cash flow grew 2.68% and total debt fell 83.6%, each against the same quarter a year earlier.
4.82
0.53
−9.91%
Follow BIOA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.41 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 52.85 | 72.02 | 106.13 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(13.14) | (16.83) | (30.90) | (57.06) | |
P/B ratio |
0.76 | 1.75 | 1.96 | 2.93 | |
Price to Tangible BV |
0.76 | 1.75 | 1.96 | 2.93 | |
EV/Sales |
0.00 | 22.01 | 35.09 | 75.56 | |
EV/EBITDA |
0.78 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
1.19 | (2.43) | (4.10) | (8.93) | |
EV/FCF |
1.18 | (0.84) | (1.49) | (3.22) | |
Quick Ratio |
11.69 | 14.00 | 24.26 | 16.62 | |
Current Ratio |
11.87 | 14.24 | 24.76 | 17.19 | |
Net Debt/EBITDA |
12.20 | 9.82 | 15.09 | 10.89 | |
Debt/Assets |
1.35% | 0.90% | 0.29% | 0.00% | |
Debt/Equity |
0.01 | 0.01 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.03 | 0.03 | 0.03 | |
Operating CF/Net income |
0.80 | 1.09 | 1.08 | 0.74 | |
Capex/Depreciation |
(0.45) | (2,244.33) | (0.41) | (4.69) | |
Interest Coverage |
(155.30) | (308.95) | (650.64) | (29,333.00) | |
Research and Development Expense of Revenue |
901.31% | 795.97% | 736.29% | 994.08% | |
Selling, General and Administrative Expense of Revenue |
325.27% | 227.45% | 279.11% | 302.69% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
135.88% | 88.43% | 153.54% | 174.17% | |
Graham Net Nets |
1.25 | 0.56 | 0.50 | 0.28 | |
Graham Number |
49.81 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
242.33% | (16.93%) | (13.72%) | (9.71%) | |
Free Cash Flow Yield |
(28.06%) | (49.87%) | (32.76%) | (22.10%) | |
Revenue per Share |
0.06 | 0.09 | 0.07 | 0.05 | |
Operating CF per Share |
(0.45) | (0.79) | (0.57) | (0.43) | |
Capex per Share |
0.00 | (4.31) | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.45) | (5.10) | (0.57) | (0.44) | |
Cash per Share |
7.97 | 7.82 | 9.02 | 7.11 | |
Shareholders Equity per Share |
7.74 | 7.57 | 8.92 | 8.36 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.74 | 7.57 | 8.92 | 8.36 | |
Free Cash Flow |
(16.07) | (183.11) | (24.07) | (19.59) | |
Working Capital |
266.34 | 266.66 | 376.03 | 311.10 | |
Capital Expenditures |
(0.02) | (154.86) | (0.03) | (0.33) | |
Net Current Asset Value |
263.20 | 263.96 | 373.33 | 308.30 | |
EV/EBIT |
0.78 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 50.31 | 0.01 | 0.13 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | 0.54 | 0.61 | |
Average Payables |
3.56 | 2.34 | 3.53 | 3.49 | |
Average Assets |
321.24 | 326.56 | 370.75 | 359.54 | |
Average Common Equity |
295.61 | 297.59 | 346.14 | 334.85 |
Columns are period end dates